Key statistics
On Friday, Neurocrine Biosciences Inc (NBIX:NSQ) closed at 133.46, -15.52% below its 52-week high of 157.98, set on Aug 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 134.00 |
---|---|
High | 135.00 |
Low | 132.10 |
Bid | 119.77 |
Offer | 140.00 |
Previous close | 134.92 |
Average volume | 877.19k |
---|---|
Shares outstanding | 98.97m |
Free float | 98.41m |
P/E (TTM) | 45.73 |
Market cap | 13.35bn USD |
EPS (TTM) | 2.95 USD |
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
- Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
- Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
- Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
- Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
- Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
- Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
- Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
- Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
- Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
More ▼